Course Provider
Learning Objectives
Upon completion of this activity, participants should be better able to analyze the latest efficacy and safety data on chimeric antigen receptor (CAR) T-cell and bispecific antibody therapies to inform formulary decisions for relapsed/refractory multiple myeloma (R/R MM)
Upon completion of this activity, participants should be better able to apply evidence-based strategies to optimize patient selection criteria for CAR T-cell therapies and bispecific antibodies in R/R MM management, based on patient- and disease-specific factors
Upon completion of this activity, participants should be better able to assess the impact of early identification and management of adverse events (AEs) in patients receiving CAR T-cell therapies and bispecific antibodies to enhance safety and reduce costs
Upon completion of this activity, participants should be better able to evaluate the cost-effectiveness and financial implications of utilizing CAR T-cell therapies and bispecific antibodies in managed care settings for R/R MM treatment
Upon completion of this activity, participants should be better able to employ strategies to mitigate financial toxicity for R/R MM patients undergoing treatment with CAR T-cell therapies and bispecific antibodies